Volume 138, Issue 3, Pages e3 (March 2010)

Slides:



Advertisements
Similar presentations
Volume 130, Issue 2, Pages (February 2006)
Advertisements

Volume 144, Issue 3, Pages e1 (March 2013)
Volume 138, Issue 2, Pages e3 (February 2010)
Volume 138, Issue 5, Pages e10 (May 2010)
Volume 144, Issue 5, Pages e10 (May 2013)
Volume 132, Issue 7, Pages (June 2007)
Volume 144, Issue 2, Pages e12 (February 2013)
Volume 123, Issue 5, Pages (November 2002)
Volume 41, Issue 2, Pages (August 2004)
Volume 140, Issue 2, Pages e1 (February 2011)
Volume 142, Issue 7, Pages e6 (June 2012)
Volume 139, Issue 1, Pages e7 (July 2010)
Volume 76, Issue 1, Pages (July 2009)
Volume 134, Issue 3, Pages e2 (March 2008)
Volume 133, Issue 5, Pages (November 2007)
Volume 142, Issue 4, Pages (April 2012)
Reciprocal Effects of Micro-RNA-122 on Expression of Heme Oxygenase-1 and Hepatitis C Virus Genes in Human Hepatocytes  Ying Shan, Jianyu Zheng, Richard.
C-kit Inhibition by Imatinib Mesylate Attenuates Progenitor Cell Expansion and Inhibits Liver Tumor Formation in Mice  Belinda Knight, Janina E.E. Tirnitz–Parker,
Volume 133, Issue 5, Pages e1 (November 2007)
Volume 135, Issue 6, Pages (December 2008)
Volume 136, Issue 5, Pages (May 2009)
Volume 140, Issue 3, Pages e3 (March 2011)
Volume 143, Issue 5, Pages e4 (November 2012)
Volume 132, Issue 1, Pages (January 2007)
Volume 136, Issue 3, Pages (March 2009)
Ira J. Fox, Stephen C. Strom  Gastroenterology 
Jack C. Reidling, Nils Lambrecht, Mohammad Kassir, Hamid M. Said 
Volume 140, Issue 3, Pages e10 (March 2011)
Volume 137, Issue 4, Pages e5 (October 2009)
Volume 133, Issue 3, Pages (September 2007)
Volume 135, Issue 5, Pages e3 (November 2008)
Volume 132, Issue 4, Pages (April 2007)
Volume 130, Issue 4, Pages (April 2006)
Volume 140, Issue 1, Pages (January 2011)
Volume 130, Issue 4, Pages (April 2006)
Volume 133, Issue 5, Pages (November 2007)
Volume 137, Issue 3, Pages (September 2009)
Volume 132, Issue 7, Pages (June 2007)
Volume 140, Issue 3, Pages e2 (March 2011)
Abrogation of the Antifibrotic Effects of Natural Killer Cells/Interferon-γ Contributes to Alcohol Acceleration of Liver Fibrosis  Won–Il Jeong, Ogyi.
Volume 130, Issue 2, Pages (February 2006)
Volume 134, Issue 4, Pages e2 (April 2008)
Volume 138, Issue 2, Pages e3 (February 2010)
Volume 141, Issue 1, Pages e1 (July 2011)
Volume 140, Issue 2, Pages e4 (February 2011)
Volume 143, Issue 1, Pages e7 (July 2012)
T Cell-Derived Lymphotoxin Regulates Liver Regeneration
Volume 133, Issue 4, Pages e3 (October 2007)
Volume 134, Issue 2, Pages e3 (February 2008)
Volume 132, Issue 3, Pages (March 2007)
Daniel F. Wallace, Lesa Summerville, V. Nathan Subramaniam 
Volume 138, Issue 4, Pages (April 2010)
Volume 135, Issue 3, Pages e3 (September 2008)
Volume 140, Issue 3, Pages (March 2011)
1,25-dihydroxyvitamin D3 inhibits renal interstitial myofibroblast activation by inducing hepatocyte growth factor expression  Yingjian Li, Bradley C.
Volume 136, Issue 3, Pages e2 (March 2009)
Volume 143, Issue 3, Pages e6 (September 2012)
Volume 132, Issue 4, Pages (April 2007)
Inducible Nitric Oxide Synthase Up-Regulates Notch-1 in Mouse Cholangiocytes: Implications for Carcinogenesis  Norihisa Ishimura, Steven F. Bronk, Gregory.
Volume 144, Issue 5, Pages e4 (May 2013)
Volume 134, Issue 5, Pages (May 2008)
Volume 130, Issue 2, Pages (February 2006)
M.-J. Wu, M.-C. Wen, Y.-T. Chiu, Y.-Y. Chiou, K.-H. Shu, M.-J. Tang 
Timothy P. Sheahan, Charles M. Rice  Gastroenterology 
Volume 131, Issue 2, Pages (August 2006)
Volume 128, Issue 5, Pages (May 2005)
Volume 122, Issue 7, Pages (June 2002)
Volume 156, Issue 4, Pages (March 2019)
Intestinal myofibroblasts in innate immune responses of the intestine
Volume 131, Issue 5, Pages (November 2006)
Presentation transcript:

Volume 138, Issue 3, Pages 1123-1133.e3 (March 2010) Cell-Type Specific Gene Expression Signature in Liver Underlies Response to Interferon Therapy in Chronic Hepatitis C Infection  Limin Chen, Ivan Borozan, Jing Sun, Maha Guindi, Sandra Fischer, Jordan Feld, Nitasha Anand, Jenny Heathcote, Aled M. Edwards, Ian D. McGilvray  Gastroenterology  Volume 138, Issue 3, Pages 1123-1133.e3 (March 2010) DOI: 10.1053/j.gastro.2009.10.046 Copyright © 2010 AGA Institute Terms and Conditions

Figure 1 Hierachial clustering analysis of 78 CHC liver samples based on expression levels of 18 previously defined signature genes. Hierarchial clustering analysis was performed based on the expression levels of 18 previously defined genes.16 The analysis broadly separates patients into 2 groups: responders (R) and nonresponders (NR). Gastroenterology 2010 138, 1123-1133.e3DOI: (10.1053/j.gastro.2009.10.046) Copyright © 2010 AGA Institute Terms and Conditions

Figure 2 Multivariate ANOVA analysis of genes altered by chronic HCV infection. (A) Response status excluded: The bar graph shows the number of genes significantly associated with each factor (genotype/disease [D], gender [G], viral load [V], fibrosis [F], and inflammation [I]). Genotype was associated with the most genes (17). The box plots below show the distribution of fold differences in gene expression between the levels of each factor for significant genes associated with each factor. (B) Response status included: In this analysis, response status (R) was considered in addition to the 5 previous factors. Response status was associated with the most genes (24). Gastroenterology 2010 138, 1123-1133.e3DOI: (10.1053/j.gastro.2009.10.046) Copyright © 2010 AGA Institute Terms and Conditions

Figure 3 Hierarchical cluster plot of genotype 1 patients segregated by “genotype”-specific genes. The 17 genes shown on the right of the plot were significantly associated with “genotype/disease” using the ANOVA multivariate model. There are 2 main clusters, with nonresponders being significantly enriched in one and responders in the other (see Results section). Gastroenterology 2010 138, 1123-1133.e3DOI: (10.1053/j.gastro.2009.10.046) Copyright © 2010 AGA Institute Terms and Conditions

Figure 4 ISG activation in different cell types in pretreatment R and NR liver. (A) Quantitation of hepatocyte and macrophage expression of ISG15 protein in pretreatment liver biopsy specimens of R (n = 15) and NR (n = 16) patients, evaluated as per Patients and Methods section. Data are mean ± SD; *P < .005 and **P < .0001 between R and NR samples. (B) Quantitation of hepatocyte and macrophage expression of MxA protein in pretreatment liver biopsy specimens of R (n = 15) and NR (n = 16) patients as in A. Data are mean ± SD; *P = .0036 and **P < .001 between R and NR samples. (C) Representative ISG15 immunohistochemistry. (a) Representative liver biopsy from NR patient immunostained for ISG15 showing predominantly hepatocellular pattern of immunoreactivity (original magnification, 50×); (b) liver biopsy from same NR patient as in a, immunostained for ISG15, showing detail of hepatocellular staining at high power (original magnification, 400×); (c) representative liver biopsy from R patient, immunostained for ISG15, showing macrophage pattern of immunoreactivity (original magnification, 50×); (d) liver biopsy from same R patient as in c, immunostained for ISG15, showing detail of macrophage staining in high power (original magnification, 400×). (D) Macrophage-specific staining. (a) Liver biopsy from R patient, immunostained for ISG15, showing typical macrophage pattern of immunoreactivity in sinusoidal lining cells (original magnification, 400×); (b) liver biopsy from the same patient as in a, immunostained for smooth muscle actin, showing no reaction in sinusoidal lining cells (original magnification, 400×); (c) liver biopsy from same patient, immunostained for CD68, showing immunoreactivity in sinusoidal lining cells similar in morphology and location to the ISG15 immunoreactive cells in a (original magnification, 400×). Gastroenterology 2010 138, 1123-1133.e3DOI: (10.1053/j.gastro.2009.10.046) Copyright © 2010 AGA Institute Terms and Conditions

Figure 5 ISG15-specific immunohistochemical staining. (A) Recombinant ISG15 protein attenuates ISG15 antibody binding in vitro in a dose-dependent manner. Shown is a Western blot for ISG15: 10 ng of separated, purified human ISG15 was transferred to each of 6 nitrocellulose membrane lanes. Individual lanes were incubated with a mixture of mouse anti-human ISG15 polyclonal antibody (1:300) and ISG15 purified protein (ng/mL) 0 (lane 1), 2 (lane 2), 20 (lane 3), 200 (lane 4), 2000 (lane 5), and 4000 (lane 6) for 2 hours. The ISG15 signal was attenuated (quenched by) the higher amounts of purified ISG15 protein. (B) Confirmation of ISG15-specific staining in immunohistochemical analysis: (a) Liver biopsy from R patient, immunostained using mAb for MxA, showing typical macrophage pattern of immunoreactivity (original magnification, 200×); (b) liver biopsy from the same R patient as in a, first quenched with ISG15 protein (2 μg/mL) and then immunostained with the MxA antibody, showing persistence of immunoreactivity and indicating no cross-reaction between MxA antibody and ISG15 protein (original magnification, 200×); (c) liver biopsy from NR patient, immunostained for ISG15, showing typical hepatocellular pattern of immunoreactivity (original magnification, 200×); (d) liver biopsy from same NR patient as in c, first quenched with ISG15 protein (2 μg/mL) and then immunostained for ISG15, showing loss of immunoreactivity and indicating no cross-reaction between the ISG15 antibody and MxA or other protein (original magnification, 200×). Gastroenterology 2010 138, 1123-1133.e3DOI: (10.1053/j.gastro.2009.10.046) Copyright © 2010 AGA Institute Terms and Conditions

Supplementary Figure 1 Real-time PCR of indicated genes in normal liver tissues (n = 10, open), pretreatment liver tissues from HCV treatment responders (n = 10, shaded), pretreatment liver tissues from HCV treatment nonresponders (n = 10, solid). All HCV liver biopsy specimens were taken prior to initiation of treatment with PegIFN and ribavirin. Responder and nonresponder liver tissue had similar viral loads, and all HCV biopsy specimens were obtained from genotype 1 patients. Gastroenterology 2010 138, 1123-1133.e3DOI: (10.1053/j.gastro.2009.10.046) Copyright © 2010 AGA Institute Terms and Conditions